I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $379.25M

Company

Location

Date

Amt. (M)

Details


Arrow Therapeutics
Ltd.

London

10/1

£21 (US$35)

Atlas Venture led the Series B round, which is expected to be the round's first closing; other investors were NIF and ITX of Japan and Scottish Widows Investment Partnership, along with previous investors that also participated

Barrier
Therapeutics
Inc.

Princeton, N.J.

10/27

$32

Barrier raised $32M in a Series C financing; MPM Capital led the round, which included all of the company's previous institutional investors

Biospect Inc.

South San Francisco

10/21

$27

Biospect raised $27M in a Series A financing; investors were Advent Venture Partners, Prospect Venture Partners, Venrock Associates and Versant Ventures

BioVex Ltd.

Oxford, UK

10/6

£17 (US$28.3)

BioVex raised US$28.3M in a third round of financing; Scottish Equity Partners led the round that included ABN AMRO Capital, Avalon Ventures, Credit Lyonnais Private Equity and Sitka Health Fund VCT, all new investors; all the company's major existing investors also participated

CellzDirect Inc.

Tucson, Ariz.

10/20

$2

CellzDirect raised $2M in a financing that included existing investors Valley Ventures, Solstice Capital, Technology Funding and Village Ventures

Collegium
Pharmaceutical
Inc.

Cumberland, R.I.

10/28

ND

Collegium raised an undisclosed amount from a Series A financing; Boston Millennia Partners was the investor

CoTherix Inc.*
(formerly Exhale
Therapeutics Inc.)

Belmont, Calif.

10/14

$55

CoTherix raised $55M in a Series C round; MPM Capital led the financing, along with Sofinnova Partners, Frazier Healthcare Ventures, Thomas Weisel Healthcare Ventures and existing investors

Critical
Therapeutics
Inc.

Cambridge, Mass.

10/8

$56

CTI raised $56M in a Series B financing; Advanced Technology Ventures and Johnson & Johnson Development Corp. co-led the round, which included MedImmune Ventures, Oxford Bioscience Partners, HealthCare Ventures and MPM Capital

Elixir
Pharmaceuticals
Inc.

Cambridge, Mass.

10/13

$19

Elixir raised $19M in the second closing of its Series B round, the first part of which was $21.5M and closed in February; the investors in the new closing were not disclosed

Favrille Inc.

San Diego

10/13

$10.6

Favrille raised an additional $10.6M in its Series B round, which now totals about $33.5M; Sandering Ventures led the round, which included Forward Ventures, Alloy Ventures, De Novo Ventures, Lotus BioScience Investment Holdings Ltd., Gray Ghos LLC and Heller Financial Leasing Inc.

GenPath
Pharmaceuticals
Inc.

Cambridge, Mass.

10/1

$42.7

GenPath raised $42.7M in a Series B financing; Flagship Ventures led the round and was joined by Highland Capital Partners and Oxford Biosciences, as well as private European investors and Series A investors

Metabasis
Therapeutics Inc.

San Diego

10/28

$24.9

Investors in the company's third financing round included Maverick Capital, Wellcome Trust, ITOCHU Corp., Pan-Pacific Venture Capital and the three major existing investors

Miikana
Therapeutics
Inc.

Toronto and Fremont, Calif.

10/1

$4.25

The Series A financing was led by 5AM Ventures and Aravis Ventures, and included Novartis Venture Fund and Queensland Asset Management

Neuvolution A/S

Copenhagen, Denmark

10/9

$15

Neuvolution raised $15M in the first closing of its Series B financing; Scandinavian Life Science Venture led the deal, which included SEB Foretagsinvest, Novo A/S, Nordic Biotech K/S and the Danish Investment Fund

Phenomix Corp.

San Diego

10/14

$13.5

Phenomix received $13.5M in the second tranche of its first-round funding, which brought in $10M in March 2002; Alta Partners and Sofinnova Ventures led the round, which included Bay City Capital, CMEA Ventures, GBS Venture Partners and Versant Ventures

TiGenix NV

Louvain, Belgium

10/8

€12 (US$14)

TiGenix raised €12M in its first funding round; ING Private Equity and Capricorn Venture Partners led the round, which also included Auriga Partners SA, Fagus NV and Gemma Frisius Fund

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $4.5M

Company (Symbol)#*

Partner (Country)

Amt. (M)

Triggering Event

Details (Date)


Applied Molecular Evolution Inc. (AMEV)

MedImmune Inc. (MEDI)

ND

Milestone payment

Triggered by MedImmune's filing of an invest- igational new drug application for Numax in respiratory syncytial virus (10/2)

Applied Molecular Evolution Inc. (AMEV)

Centocor Inc. (unit of Johnson & Johnson)

ND

Milestone payment

Triggered by AME providing Centocor with optimized antibody candidates that met the specified criteria (10/21)

Celltech Group plc (UK; NYSE:CLL)

Amgen Inc. (AMGN)

ND

Milestone payment

Triggered by identification of a Celltech anti- body against sclerostin in area of osteoporosis for further study (10/28)

CV Therapeutics Inc. (CVTX)

Fujisawa Healthcare Inc.

$3

Milestone payment

Triggered by start of Phase III study of CVT- 3146 as pharmacologic stress agent in cariac perfusion imaging studies (10/28)

DeCode Genetics Inc. (Iceland; DCGN)

Roche Diagnostics (Switzerland)

ND

Milestone payment

Triggered by identification of forms of a gene that confer increased risk of myocardial infarction (10/17)

Exelexis Inc. (EXEL)

Dow AgroSciences LLC

ND

Milestone payment

Triggered by identification of a target site relevant to a Dow herbicidal compound (10/7)

Genmab AS (Denmark; CSE:GEN)

F. Hoffmann-La Roche Ltd. (Switzerland)

ND

Milestone payment

The second milestone in their collaboration was triggered by reaching proof of concept with a human antibody developed by Genmab (10/27)

GPC Biotech AG (Germany; FSE:GPC)

Altana AG (Germany)

$1.5

Milestone payment

GPC earned milestones in the areas of technology transfer and drug discovery in the alliance to build an Altana research center in Waltham, Mass. (10/29)

Ligand Pharmaceuticals Inc. (LGND)

Wyeth

ND

Milestone payment

Triggered by Wyeth's decision to advance NSP-989 into Phase II studies for contraception (10/13)

Tularik Inc.
(TLRK)

Amgen Inc. (AMGN)

ND

Milestone payments

Triggered by Amgen's selection for optimization of two compounds against different cancer targets, each resulting in a payment (10/14)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

ND = Not disclosed.

CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange.

No Comments